Proteomics and metabolomics

The broad field of proteomics is an essential technology in biosciences that underpins strategically important areas in academia and biotechnology, enabling characterisation and temporal and spatial quantitation of proteins at various locations in practically all biological systems. It also affords measurement and discovery of post-translational protein modifications, protein-protein interactions and protein properties, which are amongst the most sought after applications.

Metabolomics is a rapidly emerging discipline dedicated to the global study of metabolites in biological systems, their dynamics, composition, interactions, and responses to interventions. The metabolome can be studied as an intermediate phenotype linking the genotype and the environment.

Contact persons & Feedback

Technology platform services

Proteomics

Service providers

Helsinki
Institute of Biotechnology Proteomics Unit
Meilahti Clinical Proteomics Core Facility

Oulu
BCO Facility

Turku
Turku Proteomics Facility

Protein characterisation

Service providers

Oulu
BCO Facility

Tampere
BioMediTech Protein Technologies

Metabolomics

Service providers

Helsinki
BCH Metabolomics Unit
- plant metabolomics and metabolomic profiling; targeted and non-targeted analysis of microbial metabolites, analysis of drug metabolites and other synthesis products.

FIMM Metabolomics Unit
- high-throughput targeted quantitative metabolomics.

Kuopio
BCK Metabolomics Center
- non-targeted metabolite profiling for various sample types incl. biofluids, tissues and in vitro material.

Contact persons & Feedback

Proteomics & metabolomics service user surveys
Contact persons

Coordinator of the Proteomics and Metabolomics Infrastructure Network
Vesa Hytönen / vesa.hytonen(at)uta.fi
BioMediTech, Tampere 

BF Protein-proteome technology platform partners:
TBA, BioCity; Marc Baumann, BCH, Meilahti Clinical Proteomics Core Facility; Markku Varjosalo, BI, Proteomics Unit; Kalervo Hiltunen, BCO, Proteomics and Protein Analysis Core Facility; Vesa Hytönen, BioMediTech, Protein Technologies Facility

BF Metabolomics technology platform partners:
Seppo Auriola, BCK & Department of Pharmaceutical Chemistry (Chair of the consortium); Tapio Palva, BCH, Metabolomics Unit; Vidya Velagapudi, FIMM, Metabolomics Laboratory